Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
- 529 Downloads
Saxagliptin is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing. Saxagliptin is metabolized in vivo to form an active metabolite, and both parent drug and metabolite are excreted primarily via the kidneys. Saxagliptin reduces the degradation of the incretin hormone glucagon-like peptide-1, thereby enhancing its actions, and is associated with improved β-cell function and suppression of glucagon secretion. Clinical trials of up to 24 weeks duration have shown that saxagliptin improves glycemic control in monotherapy and provides additional efficacy when used in combination with other oral antidiabetic agents (metformin, sulfonylurea, thiazolidinedione). Both fasting and postprandial glucose concentrations are reduce leading to clinically meaningful reductions in glycated hemoglobin, and due to the glucosedependency of its mechanism of action, there is a low risk of hypoglycemia. Saxagliptin is reported to be well tolerated with a side-effect profile similar to placebo. It has a neutral effect on body weight and dose adjustment because of age, gender, or hepatic impairment is not necessary. Saxagliptin is being co-developed by Bristol-Myers-Squibb (New York, NY, USA) and AstraZeneca (Cheshire, UK), and is currently undergoing regulatory review.
Keywordsdipeptidyl peptidase-4 DPP-4 GLP-1 glucagon-like peptide-1 glycemic control incretin enhancer saxagliptin type 2 diabetes
Unable to display preview. Download preview PDF.
- 12.Kirby MS, Dorso C, Wang A, et al. In vitro enzymologic characteristics of saxagliptin, a highly potent and selective DPP4 inhibitor with “slow binding” characteristic [abstract]. Clin Chem Lab Med. 2008;46:A29.Google Scholar
- 14.Patel C, Castaneda L, Frevert U, Li L, Kornhauser DM, Boulton DW. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects [abstract]. Diabetes. 2008;57(suppl 1.):A160.Google Scholar
- 15.Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin 2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325:175–182.PubMedCrossRefGoogle Scholar
- 16.Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of oncedaily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects [abstract]. Diabetes. 2007;56(suppl 1.):A161.Google Scholar
- 17.Boulton DW, Goyal A, Li L, Kornhauser DM, Frevert U. The effects of age and gender on the singledose pharmacokinetics and safety of saxagliptin in healthy subjects [abstract]. Diabetes. 2008;57(suppl 1.):A164.Google Scholar
- 19.Rosenstock J, Aguilar-Salinas CA, Klein E, List J, Blauwet MB, Chen R. Once-daily saxagliptin monotherapy improves glycemic control in drug-naïve patients with type 2 diabetes [abstract]. Diabetes. 2008;57(suppl 1.):A154.Google Scholar
- 20.Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009. In press.Google Scholar
- 21.DeFronzo RA, Hissa M, Blauwet MB, Chen RS. Saxagliptin added to metformin improves glycemic control in patients with type 2 diabetes [abstract]. Diabetes. 2007;56(suppl 1.):A74.Google Scholar
- 22.Ravichandran S, Chacra AR, Tan GH, Apanovitch AM, Chen R. Saxagliptin added to a sub-maximaldose sulfonylurea is safe and more efficacious than up-titrating a sulfonylurea in patients with type 2 diabetes [abstract]. Diabetologia. 2008;51(suppl 1.):S342.Google Scholar
- 23.Hollander P, Allen E, Li J, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with inadequately controlled type 2 diabetes [abstract]. Diabetologia. 2008;51 (suppl 1.):S342.Google Scholar
- 25.Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141–151.PubMedCrossRefGoogle Scholar
- 26.Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007;50:6450–6453.PubMedCrossRefGoogle Scholar
- 31.Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63:46–55.PubMedCrossRefGoogle Scholar
- 34.Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194–205.PubMedCrossRefGoogle Scholar
- 38.Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733–745.PubMedCrossRefGoogle Scholar
- 41.Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–1568.PubMedCrossRefGoogle Scholar
- 42.Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166–174.PubMedCrossRefGoogle Scholar
- 46.DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943–2952.PubMedCrossRefGoogle Scholar
- 51.European public assessment report for Galvus (vildagliptin). European Medicines Agency web site. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf. Accessed January 14, 2009.